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bases (MEDLINE, EMBASE, SCIENCE CITATION INDEX, NHSEED, HEED, CEA REGISTRY, 
RePEc, HTA database) for manuscripts published between January 2003 and November 
2013. Results were assessed for relevance by two reviewers. For eligible studies, data 
extracted included objectives, costing methodology, sources of data, disaggregated 
and aggregated costs, and conclusions. Results: Of 2094 de-duplicated references 
identified from the combined search, 57 manuscripts remained after review of titles/
abstracts and 40 after full-text review. The majority (n= 35) of studies used retrospec-
tive data; the most common study country was the US (n= 16); most studies (n= 36) 
reported direct costs only. There were four national level costing studies. Societal costs 
for ESRD in Canada totalled $CAN 1.857 billion (2000); cost of RRT in England was £780 
million (2009–2010); total public budgetary impact of Spain’s RRT programme was 
€ 1,829 million (including indirect costs) in 2010; health costs of ESRD patients with 
diabetes was $3,611 million in the US and £184.5 million in the UK in 2001. Annual per-
patient ESRD health care costs ranged from $US 36,917 (PPP, 2004) in Australia, to $US 
96,014 (2002) in US patients with diabetes. Studies also reported national and patient 
level costs for transplant and dialysis. ConClusions: A number of COI studies have 
quantified the cost of ESRD and demonstrate the substantial economic burden associ-
ated with the management of these patients.
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objeCtives: To assess the feasibility and VOI of conducting a definitive RCT to deter-
mine whether invasive urodynamic testing (IUT) is cost-effective compared with 
clinical assessment in women prior to surgery for stress (SUI) or stress predominant 
mixed urinary incontinence (MUI) and to rehearse the economic evaluation for a 
definitive RCT. Methods: Cost-utility analysis was performed alongside a pilot RCT. 
222 participants were randomised to receive IUT (‘IUT’ arm) or clinical assessment 
(‘no IUT’ arm) before surgery. Health service resource use, costs, utility values (from 
EQ-5D-3L and SF-12) and quality-adjusted life years (QALYs) were calculated. Expected 
value of sampling information (EVSI) analysis was used to determine the expected 
net gain (ENG) of additional information and the optimal sample size needed to 
maximise ENG in a future trial. Results: At 6 months the average cost incurred in 
the ‘IUT’ arm was £154 less than the ‘no IUT’ arm (95% bootstrapped CI -315 to 24) 
and there was no evidence of a difference in effects (-0.019 QALYs, 95% bootstrapped 
CI -0.0258 to 0.0133). ‘IUT’ generated an incremental cost per QALY of £8090. A sto-
chastic analysis showed that at a zero-willingness to pay threshold the IUT was 96% 
likely to be cost-effective. The VOI analysis suggested there would be added value 
from additional research to confirm which treatment is more efficient. The ENG was 
estimated to be £91m and to maximise ENG a sample size of 105 complete cases in 
each treatment arm is required. ConClusions: There was no significant difference 
in QALYs between study arms, the ‘no IUT’ arm incurred a higher average cost but 
only short-term NHS costs were considered. Our results should be interpreted with 
caution due to the limitations within our analysis. The EVSI analysis confirmed that 
there is additional value to be gained from a definitive study in this area.
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objeCtives: To investigate the preference among individuals practicing clean inter-
mittent catheterization (CIC) on a daily basis for urinary catheters that can reduce 
the frequency of urinary tract infections (UTIs). Methods: A questionnaire was 
sent by e-mail to 769 catheter users from Germany, Italy, Sweden, the UK and the 
USA through a database held by Wellspect HealthCare. The participants were asked 
to assume a situation in which they use their current catheter but have the choice 
to switch to a similar catheter, which hypothetically would reduce the frequency 
of UTIs including possible complications. Either every fourth or every second UTI 
could be avoided. The participants’ willingness-to-pay for the new catheter was 
collected by letting them choose to spend either one of eleven explicit monthly 
amounts from € 0-€ 100 or any other amount in an open answer. The participants 
also reported their UTI frequency. Only individuals stating that they were “certain” 
or “very certain” regarding their answers were included in the analyses. Results: 
429 (response rate 56%) individuals returned the questionnaire, of which 278 (65%) 
were certain or very certain regarding their answers. The proportion of respondents 
with ≤ 1 UTI/y and > 1 UTI/y were 47% and 53%, respectively. The respondents were 
willing to spend on average € 16 each month to avoid every fourth UTI and € 22 each 
month to avoid every second UTI. The willingness-to-pay was higher among the 
users with > 1 UTI/y both to avoid every fourth and every second UTI (€ 21 vs € 11 and 
€ 30 vs € 15, respectively). These differences in willingness-to-pay were statistically 
significant (p< 0.05).ConClusions: The CIC users in this study, who practice inter-
mittent catheterization on a daily basis, expressed a clear preference for catheters 
that could help to decrease the frequency of urinary tract infections (UTI).
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system. The model took into account the cost of drugs, disposables (e. g. incontinence 
pads) and devices, procedures, monitoring costs, and the cost of managing adverse 
events. Model input data were derived from the Spanish Ministry of Health, published 
and unpublished clinical studies, clinical guidelines, and expert opinion. Results: In 
the Spanish population, an estimated 96,360 individuals were eligible for treatment 
with OnabotulinumtoxinA for OAB. Compared to a current treatment pattern in which 
5% of patients received OnabotulinumtoxinA, increasing OnabotulinumtoxinA usage 
annually from 10% in year 1 to 30% in year 5 resulted in an estimated cost saving of 
€ 26.4 million over five years. This saving represented a 4.7% decrease in overall spend-
ing compared to the current treatment pattern. Increased drug acquisition costs were 
entirely offset by savings due to decreased use of incontinence pads and anticholiner-
gic therapy. ConClusions: Costs associated with inadequate management of UI due 
to OAB are significant and avoidable. Our model estimated that managing patients 
with OnabotulinumtoxinA may reduce the economic burden to the Spanish health 
care system, with increased acquisition costs of OnabotulinumtoxinA completely 
offset by savings due to decreased resource use.
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objeCtives: Chronic kidney disease (CKD) is leading condition of several comorbidi-
ties with additional social economic burden. The study aims to estimate the economic 
impact of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) on the 
social cost of a patient with CKD (stage IV and V pre-dialyses) in Italy. Methods: All 
adult outpatients in charge of 14 main Hospitals Centers in Tuscany Region have been 
enrolled during 7 week in the cross sectional study. Direct medical costs have been 
estimated using tariff for laboratory test, diagnostic exams, visits and hospitalization 
and price for drugs. Non medical costs included the cost of diet, patients and car-
egivers travel expenses, domestic help and informal care. The loss of productivity of 
patients and caregivers have been estimated as indirect costs using the human capital 
approach. The incremental effects of having comorbidities on social cost of CKD were 
estimated by multivariate Generalized Linear Models (log link, Gamma family) adjust-
ing for gender, age and stage of CKD. Costs are expressed in Euro 2012. Results: 
Among 484 CKD patients enrolled, CVD and T2DM have been found respectively in 
214 (44%) and 171 (35%) patients. The raw estimated mean annual social costs were 
€ 11,375 (± € 7,480) per patient with CKD-CVD and € 11,627 (± € 7,657) per patient with 
CKD-T2DM. Direct non medical costs and indirect costs accounted respectively for 
31% and 23% of social cost for CKD-CVD and 30% and 22% for CKD-T2DM. The incre-
mental effects of having comorbidities on the overall social cost of CKD were € 2,928 
(95% CI: € 1,680-€ 4,176, p= 0.000) for CVD and € 2,640 (95% CI: € 1,301-€ 3,979, p= 0.000) 
for T2DM. ConClusions: CVD and T2DM significantly increase the social cost of 
CKD due to the rise of the medical component. However the burden of the disease is 
mainly sustained by patients, their families and the productivity system.
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objeCtives: Urinary tract infections (UTIs) are the second most common bacterial 
infection in primary care and are often treated empirically with antibiotics. However, 
outside of the United States, there has been a lack of systematic cost-of-illness stud-
ies to assess the economic cost of UTIs in the community. The objective of this study 
was to estimate the economic cost of UTIs in Ireland from the perspective of the 
health service. Methods: We conducted a secondary analysis of a dataset which 
contained information on adult patients (excluding pregnant women) presenting to 
their General Practitioner (GP) with a suspected UTI. Data was collected from 22 GP 
practices in the West of Ireland over a 9 month period from September 2009 to May 
2010. Results from microbiological analysis to determine a positive urine culture 
were obtained from the University Hospital Galway laboratory. Health care costs were 
estimated on the basis of GP consultation costs, antibiotic costs, laboratory costs and 
secondary inpatient and outpatient costs. The latter was acquired from national clini-
cal data on discharges in acute hospitals. Results: Of the 2,850 GP consultations, 
almost 70% of the urine samples showed no laboratory evidence of a UTI. 57% of 
the patients were prescribed an antibiotic and 11% of patients re-consulted within 
one month. Total primary care costs (including antibiotics) to treat suspected UTIs 
across the 22 practices was approximately € 343,000 annually. Extrapolating results 
to a national level, the annual estimated primary care costs are approximately 
€ 19.2 million. The annual cost of UTIs in secondary care is low at approximately 
€ 155,000. ConClusions: Suspected UTIs are a common reason to attend primary 
care services in Ireland. From the health service perspective, the overall economic 
cost of UTIs is mainly driven by primary care costs with comparatively low second-
ary care costs.
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objeCtives: End-stage renal disease (ESRD) is a debilitating medical condition of 
chronic kidney failure. In ESRD, the kidneys are permanently impaired and patients 
require renal replacement therapy (RRT). In order to understand the economic bur-
den of ESRD, this scoping literature review was undertaken to identify published 
cost of illness (COI) studies in ESRD. Methods: The search strategy identified stud-
ies quantifying the economic burden of ESRD in selected countries (USA, Canada, 
Australia, Japan, UK, France, Germany, Spain, and Italy). We searched electronic data-
